Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 19/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | FLT4 | P35916 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | CLK1 | P49759 | 1/20 | 0.59 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.59 |
| ▸ | TEK | Q02763 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26082 | 0.94 | EGFR (0.61) | FBP1EGFRAURKAERBB2INSR | |
| SCHEMBL15928220 | 0.93 | EGFR (0.61) | FBP1EGFRAURKAERBB2INSR | |
| SCHEMBL19293607 | 0.93 | FBP1 (0.66) | FBP1EGFRAURKAERBB2INSR | |
| SCHEMBL15928079 | 0.93 | FBP1 (0.60) | FBP1EGFRAURKAERBB2INSR | |
| SCHEMBL6987785 | 0.92 | EGFR (0.70) | FBP1EGFRAURKAERBB2INSR | |
| SCHEMBL3575576 | 0.91 | EGFR (0.64) | FBP1EGFRAURKAERBB2INSR | |
| SCHEMBL642350 | 0.91 | EGFR (0.64) | FBP1EGFRAURKAERBB2INSR | |
| SCHEMBL6995758 | 0.90 | EGFR (0.63) | EGFRERBB2KDR | |
| SCHEMBL17538495 | 0.90 | EGFR (0.63) | FBP1EGFRAURKAERBB2INSR | |
| SCHEMBL16212087 | 0.90 | FBP1 (0.76) | FBP1EGFRAURKAERBB2INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-02-05 | — | — | US | disclosed |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| EP-3181553-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181553-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016023217-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 安润医药科技（苏州）有限公司 | 2016-02-18 | — | — | WO | disclosed |
| US-8846699-B2 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | HANMI PHARM. CO., LTD. (KR) | 2014-09-30 | — | — | US | disclosed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | disclosed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | WEE1, WEE2, EGFR | FBP1 2501/4885EGFR 3/4885AURKA 1244/4885 |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | FBP1 3705/4885EGFR 955/4885AURKA 280/4885 |
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | WEE1, WEE2, EGFR | FBP1 2501/4885EGFR 3/4885AURKA 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.